Recombinant Human IL-28B/IFN-lambda 3 Protein, CF

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human IL-28B/IFN-lambda 3 Protein, CF Summary

• Details of Functionality: Measured in an anti-viral assay using HepG2 human hepatocellular carcinoma cells infected with encephalomyocarditis (EMC) virus. Sheppard, P. et al. (2003) Nat. Immunol. 4:63. The ED₅₀ for this effect is 0.0800-0.800 ng/mL.
• Source: Chinese Hamster Ovary cell line, CHO-derived human IL-28B/IFN-lambda 3 protein
  Arg30-Val200, with the variant of Lys74Arg and a C-terminal 6-His tag
• Accession #: AAN28264
• N-terminal Sequence: Arg30
• Protein/Peptide Type: Recombinant Proteins
• Gene: IFNL3
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 20.1 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 22 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS, NaCl and EDTA.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 100 μg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human IL-28B/IFN-lambda 3 Protein, CF

• interleukin-28B
• IFN-lambda 3
• IL28B
• IL-28B
• IL28C
• interferon, lambda 3

Background

IL-28B (also named interferon-lambda 3, IFN-lambda 3), IL-28A (IFN-lambda 2) and IL-29 (IFN-lambda 1) are type III interferons that are class II cytokine receptor ligands (1-4). They are distantly related to members of the IL-10 family and type I IFN family (1- 4). Human IL-28B cDNA encodes a 200 amino acid (aa) protein with a 25 aa signal peptide and a 175 aa mature protein that lacks N-glycosylation sites. Mature human IL-28B shares 64% and 75% aa sequence identity with mouse and canine IL-28B, respectively, and is active across species (5). Human IL-28B shares 94% and 69% aa identity with human IL-28A and IL‑29, respectively (4). Type III interferons are widely expressed, but are mainly produced by antigen presenting cells in response to viruses and double-stranded RNA that interact with Toll-like receptors or RIG-1 family helicases (2-6). They signal through a widely expressed receptor that is a heterodimer of the IL-10 receptor beta (IL-10 R beta ) and IL-28 receptor alpha (IL-28 R alpha ; also called IFN-lambda R1) (2, 3, 7, 9). Interaction of either type I or type III IFNs with their receptors activates similar pathways, including JAK tyrosine kinase activation, STAT phosphorylation and formation of the IFN-stimulated regulatory factor 3 (ISGF-3) transcription factor complex (1-3). Both type I and III IFNs induce anti‑viral activity and up‑regulate MHC class I antigen expression (2-6). Cell lines responsive to type III IFNs are also responsive to type I IFNs, but in general, higher concentrations of type III IFNs are needed for similar in vitro responses (8). In vivo, however, type III IFNs enhance levels of IFN-gamma in serum, suggesting that the robust anti-viral activity of type III IFNs may stem in part from activation of the immune system (5, 7). Anti-proliferative and antitumor activity in vivo has also been shown for type III IFNs (9-11).

1. Chen, Q. et al. (2006) Vitam. Horm. 74:207.
2. Sheppard, P. et al. (2003) Nat. Immunol. 4:63.
3. Kotenko, S.V. et al. (2003) Nat. Immunol. 4:69.
4. Bartlett, N.W. et al. (2005) J. Gen. Virol. 86:1589.
5. Ank, N. et al. (2006) J. Virol. 80:4501.
6. Onoguchi, K. et al. (2007) J. Biol. Chem. 282:7576.
7. Siebler, J. et al. (2007) Gastroenterology 132:358.
8. Meager, A. et al. (2005) Cytokine 31:109.
9. Lasfar, A. et al. (2006) Cancer Res. 66:4468.
10. Sato, A. et al. (2006) J. Immunol. 176:7686.
11. Zitzmann, K. et al. (2006) Biochem. Biophys. Res. Commun. 344:1334.

Publications for IL-28B/IFN-lambda 3 (5259-IL/CF)(25)

Publications using 5259-IL/CF

• A Erb, UM Zissler, M Oelsner, AM Chaker, CB Schmidt-We, CA Jakwerth Genome-Wide Gene Expression Analysis Reveals Unique Genes Signatures of Epithelial Reorganization in Primary Airway Epithelium Induced by Type-I, -II and -III Interferons Biosensors, 2022-10-26;12(11):. 2022-10-26 [PMID: 36354438] (Bioassay, Human)
• L Broadbent, CGG Bamford, G Lopez Camp, S Manzoor, D Courtney, A Ali, O Touzelet, C McCaughey, K Mills, UF Power An endogenously activated antiviral state restricts SARS-CoV-2 infection in differentiated primary airway epithelial cells PLoS ONE, 2022-04-18;17(4):e0266412. 2022-04-18 [PMID: 35436306] (Bioassay, Human)
• M De, A Bhushan, WS Grubbe, S Roy, JL Mendoza, S Chinnaswam Distinct molecular phenotypes involving several human diseases are induced by IFN-lambda3 and IFN-lambda4 in monocyte-derived macrophages Genes and immunity, 2022-02-03;0(0):. 2022-02-03 [PMID: 35115664] (Bioassay, Human)
• T Gan, D Zhou, Y Huang, S Xiao, Z Ma, X Hu, Y Tong, H Yan, J Zhong Development of a New Reverse Genetics System for Ebola Virus mSphere, 2021-05-05;6(3):. 2021-05-05 [PMID: 33952663] (Bioassay, Human)
• I Kimura, Y Konno, K Uriu, K Hopfensper, D Sauter, S Nakagawa, K Sato Sarbecovirus ORF6 proteins hamper induction of interferon signaling Cell Reports, 2021-03-12;34(13):108916. 2021-03-12 [PMID: 33765414] (Bioassay, Human)
• X Zhao, C Li, X Liu, MC Chiu, D Wang, Y Wei, H Chu, JP Cai, I Hau-Yee Ch, K Kak-Yuen W, J Fuk-Woo Ch, K Kai-Wang T, KY Yuen, J Zhou Human Intestinal Organoids Recapitulate Enteric Infections of Enterovirus and Coronavirus Stem Cell Reports, 2021-02-12;16(3):493-504. 2021-02-12 [PMID: 33626333] (Bioassay, Primate - C. aethiops)
• HK Lee, O Jung, L Hennighaus Activation of Interferon-Stimulated Transcriptomes and ACE2 Isoforms in Human Airway Epithelium Is Curbed by Janus Kinase Inhibitors Research square, 2020-12-11;0(0):. 2020-12-11 [PMID: 33330857] (Cell Culture, Human)
• M De, A Bhushan, S Chinnaswam Monocytes differentiated into macrophages and dendritic cells in the presence of human IFN-&amp;lambda3 or IFN-&amp;lambda4 show distinct phenotypes J Leukoc Biol, 2020-11-17;0(0):. 2020-11-17 [PMID: 33205487] (Cell Culture, Human)
• OO Onabajo, AR Banday, ML Stanifer, W Yan, A Obajemu, DM Santer, O Florez-Var, H Piontkivsk, JM Vargas, TJ Ring, C Kee, P Doldan, DL Tyrrell, JL Mendoza, S Boulant, L Prokunina- Interferons and viruses induce a novel truncated ACE2 isoform and not the full-length SARS-CoV-2 receptor Nat Genet, 2020-10-19;0(0):. 2020-10-19 [PMID: 33077916] (Bioassay, Human)
• M Syedbasha, F Bonfiglio, J Linnik, C Stuehler, D Wüthrich, A Egli Interferon-&amp;lambda Enhances the Differentiation of Naive B Cells into Plasmablasts via the mTORC1 Pathway Cell Rep, 2020-10-06;33(1):108211. 2020-10-06 [PMID: 33027651] (Bioassay, Human)
• OO Onabajo, AR Banday, W Yan, A Obajemu, ML Stanifer, DM Santer, O Florez-Var, H Piontkivsk, J Vargas, C Kee, DLJ Tyrrell, JL Mendoza, S Boulant, L Prokunina- Interferons and viruses induce a novel primate-specific isoform dACE2 and not the SARS-CoV-2 receptor ACE2 bioRxiv, 2020-07-20;0(0):. 2020-07-20 [PMID: 32743577] (Bioassay, Human)
• DM Santer, GES Minty, DP Golec, J Lu, J May, A Namdar, J Shah, S Elahi, D Proud, M Joyce, DL Tyrrell, M Houghton Differential expression of interferon-lambda receptor 1 splice variants determines the magnitude of the antiviral response induced by interferon-lambda 3 in human immune cells PLoS Pathog., 2020-04-30;16(4):e1008515. 2020-04-30 [PMID: 32353085] (Bioassay, Human)
• JH Chung, SH Hong, N Seo, TS Kim, HJ An, P Lee, EC Shin, HM Kim Structure-based glycoengineering of interferon lambda 4 enhances its productivity and anti-viral potency Cytokine, 2019-08-31;125(0):154833. 2019-08-31 [PMID: 31479875] (Bioassay, Human)
• C Good, AI Wells, CB Coyne Type III interferon signaling restricts enterovirus 71 infection of goblet cells Sci Adv, 2019-03-06;5(3):eaau4255. 2019-03-06 [PMID: 30854425] (Bioassay, Human)
• MK Holly, JG Smith Adenovirus infection of human enteroids reveals interferon sensitivity and preferential infection of goblet cells J. Virol., 2018-04-13;0(0):. 2018-04-13 [PMID: 29467318] (Bioassay, Human)
• PS Sung, SH Hong, JH Chung, S Kim, SH Park, HM Kim, SK Yoon, EC Shin IFN-?4 potently blocks IFN-? signalling by ISG15 and USP18 in hepatitis C virus infection Sci Rep, 2017-06-19;7(1):3821. 2017-06-19 [PMID: 28630501] (Bioassay, Human)
• Hepatitis-C-virus-induced microRNAs dampen interferon-mediated antiviral signaling Nat. Med., 2016-11-14;0(0):. 2016-11-14 [PMID: 27841874] (Bioassay, Human)
• Immune Cell Profiling of IFN-? Response Shows pDCs Express Highest Level of IFN-?R1 and Are Directly Responsive Via the JAK-STAT Pathway J Interferon Cytokine Res, 2016-09-12;0(0):. 2016-09-12 [PMID: 27617757] (Bioassay, Human)
• Resistin reinforces interferon ?-3 to eliminate hepatitis C virus with fine-tuning from RETN single-nucleotide polymorphisms Sci Rep, 2016-08-01;6(0):30799. 2016-08-01 [PMID: 27477870] (Bioassay, Human)
• Banos-Lara M, Harvey L, Mendoza A, Simms D, Chouljenko V, Wakamatsu N, Kousoulas K, Guerrero-Plata A Impact and regulation of lambda interferon response in human metapneumovirus infection. J Virol, 2014-10-29;89(1):730-42. 2014-10-29 [PMID: 25355870] (Bioassay, Human)
• Persson B, Jaffe A, Fearns R, Danahay H Respiratory syncytial virus can infect basal cells and alter human airway epithelial differentiation. PLoS ONE, 2014-07-17;9(7):e102368. 2014-07-17 [PMID: 25033192] (Bioassay, Human)
• Ding S, Khoury-Hanold W, Iwasaki A, Robek M Epigenetic reprogramming of the type III interferon response potentiates antiviral activity and suppresses tumor growth. PLoS Biol, 2014-01-07;12(1):e1001758. 2014-01-07 [PMID: 24409098] (Bioassay, Human)
• Stone , Amy E L, Giugliano , Silvia, Schnell , Gretja, Cheng , Linling, Leahy , Katelyn, Golden-Mason , Lucy, Gale , Michael, Rosen , Hugo R Hepatitis C virus pathogen associated molecular pattern (PAMP) triggers production of lambda-interferons by human plasmacytoid dendritic cells. PLoS Pathog, 2013-04-18;9(4):e1003316. 2013-04-18 [PMID: 23637605] (Bioassay, Human)
• Wilson TR, Fridlyand J, Yan Y, Penuel E, Burton L, Chan E, Peng J, Lin E, Wang Y, Sosman J, Ribas A, Li J, Moffat J, Sutherlin DP, Koeppen H, Merchant M, Neve R, Settleman J Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature, 2012-07-26;487(7408):505-9. 2012-07-26 [PMID: 22763448] (Bioassay, Human)
• Liu MQ, Zhou DJ, Wang X, Zhou W, Ye L, Li JL, Wang YZ, Ho WZ IFN-lambda3 inhibits HIV infection of macrophages through the JAK-STAT pathway. PLoS ONE, 2012-04-27;7(4):e35902. 2012-04-27 [PMID: 22558263] (Bioassay, Human)

Bioinformatics

• Gene Symbol: IFNL3
• Uniprot:
  • AAN28264()